Gan & Lee Pharmaceuticals Co., Ltd. initiated the first-in-human Phase 1 clinical trial for GLR2007, internally-invented, cyclin-dependent kinase 4/6 (CDK4/6) inhibitor as a potential therapy for advanced solid tumors. CDK4/6 activity is central to cell cycle regulation and has a key role in the occurrence and progression of a variety of cancers.
Therefore, Gan & Lee views CDK4/6 as an attractive therapeutic target agent. This Phase 1 clinical trial is a multicenter, open- label, study designed to establish the safety, tolerability, and optimal dosing strategy of GLR2007 in patients with advanced solid tumors. Dr. Lawrence Hill, CEO, Gan & Lee US says, “Based on encouraging pre-clinical data and the high unmet need, 3 GLR2007 is a promising new investigational compound that could potentially address unmet medical need for patients with advanced solid tumors. We are excited to begin this Phase 1 clinical study (NCT04444427) and look forward to collaborating with patients, caregivers and the medical community to make a meaningful difference to people living with cancer.”
